{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6.2.4.', 'Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Scale', '77', '6.2.5.', 'Yale Global Tic Severity Scale', '77', '6.2.6.', '77', '6.2.7.', \"Children's Yale-Brown Obsessive-Compulsive Scale\", '78', '7.', 'ASSESSMENT OF SAFETY', '79', '7.1.', 'Adverse Events', '79', '7.1.1.', 'Definition of an Adverse Event', '79', '7.1.2.', 'Recording and Reporting Adverse Events', '80', '7.1.3.', 'Severity of an Adverse Event', '80', '7.1.4.', 'Relationship of an Adverse Event to the IMP', '81', '7.1.5.', 'Serious Adverse Events', '81', '7.1.5.1.', 'Definition of a Serious Adverse Event', '82', '7.1.5.2.', 'Expectedness', '82', '7.1.5.3.', 'Reporting a Serious Adverse Event', '83', '7.1.6.', 'Protocol-Defined Adverse Events of Special Interest', '85', '7.1.7.', 'Withdrawal Due to an Adverse Event', '85', '7.1.8.', 'Protocol Deviations Because of an Adverse Event', '85', '7.2.', 'Psychometric Rating Scales', '85', '7.2.1.', 'Mini International Neuropsychiatric Interview for Children and Adolescents', '86', '7.2.2.', 'Columbia-Suicide Severity Rating Scale', '86', '7.2.3.', \"Children's Depression Inventory, Second Edition\", '87', '7.3.', 'Pregnancy', '87', '7.4.', 'Medication Error and Special Situations Related to the Investigational', 'Medicinal Product', '88', '7.5.', 'Clinical Laboratory Tests', '89', '7.5.1.', 'Serum Chemistry, Hematology, and Urinalysis', '89', '7.5.2.', 'Other Clinical Laboratory Tests', '90', '7.5.2.1.', 'Human Chorionic Gonadotrophin Test', '90', '7.5.2.2.', 'Urine Drug Screen', '90', '7.5.3.', 'Cytochrome P450 2D6 Genotyping', '91', '7.6.', 'Vital Signs', '91', '7.7.', 'Electrocardiography', '91', '7.8.', 'Physical Examinations', '92', '24']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.9.', 'Assessment of Suicidality', '92', '7.10.', 'Neurological Examinations', '93', '7.11.', 'Concomitant Therapy or Medication', '93', '7.12.', 'Methods and Timing of Assessing, Recording, and Analyzing Safety Data', '93', '8.', 'ASSESSMENT OF PHARMACOKINETICS AND SCREENING', 'ASSESSMENTS', '94', '8.1.', 'Pharmacokinetic Assessment', '94', '8.2.', 'Pharmacodynamics Assessment', '94', '8.3.', 'Pharmacogenetics', '94', '8.3.1.', 'CYP2D6 Genotyping/Pharmacogenetics', '94', '9.', 'STATISTICS', '96', '9.1.', 'Sample Size and Power Considerations', '96', '9.2.', 'Analysis Sets', '96', '9.2.1.', 'Intent-to-Treat Analysis Set', '96', '9.2.2.', 'Safety Analysis Set', '96', '9.2.3.', 'Modified Intent-to-Treat Analysis Set', '96', '9.2.4.', 'Per-Protocol Analysis Set', '96', '9.3.', 'Data Handling Conventions', '97', '9.4.', 'Study Population', '97', '9.4.1.', 'Patient Disposition', '97', '9.4.2.', 'Demographic and Baseline Characteristics', '97', '9.5.', 'Efficacy Analysis', '97', '9.5.1.', 'Primary Endpoint', '97', '9.5.2.', 'Key Secondary Endpoints', '97', '9.5.3.', 'Exploratory Endpoints', '98', '9.5.4.', 'Planned Method of Analysis', '98', '9.5.4.1.', 'Primary Efficacy Analysis', '98', '9.5.4.2.', 'Sensitivity Analysis', '99', '9.5.4.3.', 'Key Secondary Efficacy Analyses', '99', '9.5.4.4.', 'Exploratory Analyses', '99', '9.6.', 'Multiple Comparisons and Multiplicity', '100', '9.7.', 'Safety Endpoints and Analysis', '100', '9.7.1.', 'Safety Endpoints', '100', '25']\n\n###\n\n", "completion": "END"}